Centre de Recherche du CHUM, Montreal, QC, Canada.
Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada.
Nat Commun. 2023 Oct 23;14(1):6710. doi: 10.1038/s41467-023-42500-2.
The HIV-1 entry inhibitor temsavir prevents the viral receptor CD4 (cluster of differentiation 4) from interacting with the envelope glycoprotein (Env) and blocks its conformational changes. To do this, temsavir relies on the presence of a residue with small side chain at position 375 in Env and is unable to neutralize viral strains like CRF01_AE carrying His375. Here we investigate the mechanism of temsavir resistance and show that residue 375 is not the sole determinant of resistance. At least six additional residues within the gp120 inner domain layers, including five distant from the drug-binding pocket, contribute to resistance. A detailed structure-function analysis using engineered viruses and soluble trimer variants reveals that the molecular basis of resistance is mediated by crosstalk between His375 and the inner domain layers. Furthermore, our data confirm that temsavir can adjust its binding mode to accommodate changes in Env conformation, a property that likely contributes to its broad antiviral activity.
HIV-1 进入抑制剂替拉韦定可防止病毒受体 CD4(分化簇 4)与包膜糖蛋白(Env)相互作用,并阻止其构象变化。为此,替拉韦定依赖于 Env 中位置 375 处具有小侧链的残基的存在,并且无法中和携带 His375 的病毒株,如 CRF01_AE。在这里,我们研究了替拉韦定耐药的机制,并表明 375 位残基不是耐药的唯一决定因素。至少有六个额外的残基位于 gp120 内层域层内,包括远离药物结合口袋的五个残基,有助于耐药。使用工程病毒和可溶性三聚体变体进行的详细结构-功能分析表明,耐药的分子基础是由 His375 与内层域层之间的串扰介导的。此外,我们的数据证实替拉韦定可以调整其结合模式以适应 Env 构象的变化,这种特性可能有助于其广泛的抗病毒活性。